AF
ALGS icon

Amalgamated Financial’s Aligos Therapeutics ALGS Stock Holding History

Amalgamated Financial’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$7K Buy
+138
New +$11.1K ﹤0.01% 2934

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Amalgamated Financial's ALGS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Aligos Therapeutics (ALGS) in Q1 2022: 138 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #2934 among its holdings.

76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

  • Amalgamated Financial held 138 shares of Aligos Therapeutics worth $7K as of Q1 2022.
  • Aligos Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Aligos Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2934 holding.
  • 76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.